ASCO 2012 Highlights: Breaking an Impasse for KRAS Mutation-

[NikoleV]

ASCO 2012 Highlights: Breaking an Impasse for KRAS Mutation-Positive NSCLC

September 22nd, 2012 - by Dr. Jack West

http://blog.lungevity.org/2012/09/22/se ... -pos-nscl/

Dr. Joel Neal provides further highlights from ASCO 2012 with his summary of a novel therapy for KRAS mutation-positive advanced NSCLC, the most common molecular marker in NSCLC. A new treatment with activity for KRAS mutation-positive NSCLC is particularly welcome, since this is a group for which we haven’t had effective treatment options.

Dr. Neal reviews the very promising work with the MEK inhibitor selumetinib combined with Taxotere (docetaxel) vs. Taxotere alone for KRAS mutation-positive advanced NSCLC. Efficacy certainly appears encouraging, but this appears to come with a price of increased side effects that may prove to be prohibitively challenging. Still, just breaking the impasse of having something favorable for this underserved population is a welcome advance.

Below are the video and audio versions of the podcast, as well as the transcript and figures for this program. Click on the link above to view the video and listen to the audio.

Dr. Neal LC Highlights ASCO 2012 Selumetinib KRAS mutn pos Adv NSCLC Video Podcast

Dr. Neal LC Highlights ASCO 2012 Selumetinib KRAS mutn pos Adv NSCLC Audio Podcast

Dr. Neal LC Highlights ASCO 2012 Selumetinib KRAS mutn pos Adv NSCLC Transcript

Dr. Neal LC Highlights ASCO 2012 Selumetinib KRAS mutn pos Adv NSCLC Figs

Next, we’ll get Dr. Neal’s discussion of the controversial topic of post-operative EGFR inhibitor therapy for EGFR mutation-positive NSCLC after resection of an early stage cancer.